Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study - Test2 - elhamkhani - TriplyDB

Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study

Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study

http://www.wikidata.org/entity/Q35025805

about

Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study

http://www.wikidata.org/entity/Q35025805

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@ast

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@en

type

label

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@ast

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@en

prefLabel

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@ast

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@en

P1433

Q35025805-05D09DDB-900F-4080-9B87-1DE7CF38BC08

P1476

Q35025805-EB27BBCC-55C8-4D50-B1EE-EB431FF8534D

P2093

Q35025805-0EE00016-003B-415E-9407-489A75DB4DAE

Q35025805-163DDD4A-97D7-4285-B595-90C044F6128B

Q35025805-1E4F8144-4B08-4AD9-9A47-143E35676D88

Q35025805-1F600AC5-0749-47CB-956D-1EFA11585251

Q35025805-21618315-3B1A-4C89-B0D7-F2B349EAD06C

Q35025805-2B32061D-5E29-449F-984F-A6CCA2DD5562

Q35025805-50473A90-1E78-4A00-932F-8F4FA634D43C

Q35025805-572ADB57-FB92-4C8B-BFE9-1422B9C08285

Q35025805-67FB8368-9ECD-4D4F-9738-0B2067CBF0D5

Q35025805-74D2282E-FF90-45FD-B0D1-20C713D636BE

P2860

Q35025805-11283009-014B-4C83-A797-CD965F81BE3E

Q35025805-1932F8B8-5A46-44CD-A03B-5713BF66935D

Q35025805-2CBD795B-FD6B-4D1E-9F65-83575A6091C3

Q35025805-330EFD32-9B93-4193-9EC0-386C39417DCA

Q35025805-39109D94-0EBD-4000-A385-7B8B5F80F8D9

Q35025805-428F08CE-261F-4ED8-B559-8C52AB34A952

Q35025805-468AE926-8D95-4604-9FF5-15137364E89E

Q35025805-49397B2A-29B7-4E10-8F03-6AE849D0B6B7

Q35025805-5577C038-F8AE-4151-9C59-A2F43F49FEC4

Q35025805-8C6C8EFE-6EC3-4290-9A4B-35628510A903

P2888

Q35025805-BB860874-552E-4080-BEA4-CA249375B310

P304

Q35025805-E4367F96-AF53-45ED-9BE4-15D08142F853

P31

Q35025805-4F6F83E5-5661-49E0-8440-A8A004BBF858

P356

Q35025805-D3C94126-36AF-4BA0-9722-58090B995970

P478

Q35025805-927AA93E-2D97-4787-9383-E21C8865785C

P50

Q35025805-18CA9FAA-5EDD-4D00-9AC7-86A5E8B2004B

Q35025805-9C272AA2-EEBE-48B0-999B-5EF0A97FEA2C

P577

Q35025805-C6BB52F8-7ADE-49F4-A937-06268463D79B

P5875

Q35025805-0781ED4B-9D58-4138-9329-20F464FA2D81

P6179

Q35025805-633386CB-51C0-4802-A5BC-DF6602D87311

P698

Q35025805-CAFEBA02-EB13-475F-848D-BB0466E0FDF2

P921

Q35025805-3B1500F6-BB20-462A-98CB-8A8C7D5FC122

P932

Q35025805-72962443-0096-4B13-B46F-F979B2E7490A

P356

1471-2261-13-91

P1433

BMC Cardiovascular Disorders

P1476

Impact of percutaneous coronar ...... OAT) biomarker ancillary study

@en

P2093

Anna Raczynska

http://www.w3.org/2001/XMLSchema#string

Benita Busz-Papież

http://www.w3.org/2001/XMLSchema#string

Daner Li

http://www.w3.org/2001/XMLSchema#string

Elzbieta Zinka

http://www.w3.org/2001/XMLSchema#string

Grzegorz Opolski

http://www.w3.org/2001/XMLSchema#string

Grzegorz Skonieczny

http://www.w3.org/2001/XMLSchema#string

Jacek Kądziela

http://www.w3.org/2001/XMLSchema#string

Jadwiga Janas

http://www.w3.org/2001/XMLSchema#string

Krystyna Jaworska

http://www.w3.org/2001/XMLSchema#string

Marek Roik

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin

The late open artery hypothesis--a decade later.

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

Matrix metalloproteinases: regulation and dysregulation in the failing heart.

The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone

Coronary intervention for persistent occlusion after myocardial infarction

Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.

Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study

Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.

P2888

1471-2261-13-91

P304

91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2261-13-91

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Judith S Hochman

Krzysztof Zmudka

P577

2013-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258042397

http://www.w3.org/2001/XMLSchema#string

P6179

1040120640

http://www.w3.org/2001/XMLSchema#string

P698

24156746

http://www.w3.org/2001/XMLSchema#string

P921

P932

3871016

http://www.w3.org/2001/XMLSchema#string